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Abstract 
The COVID-19 pandemic has resulted in increased 
need for diagnostic testing using reverse 
transcriptase real-time PCR (RT-PCR). An 
exponential increase in demand has resulted in a 
shortage of numerous reagents in particular those 
associated with the lysis buffer required to extract 
the viral RNA. Herein, we describe a rapid collective 
effort by hospital laboratory scientists, academic 
researchers and the biopharma industry to 
generate a validated lysis buffer. We have 
formulated a 4M Guanidinium thiocyanate (GITC)/ 
Triton X-100 Lysis buffer which provides 
comparable results with the recommended 
reagents. This buffer will ease the burden on 
hospital labs in their heroic efforts diagnose a large 
population of patients. 
Introduction 
The global demand for reagents for real-time 
reverse transcriptase PCR (RT-PCR) diagnostic tests 
for COVID-19 has caused a bottle neck across 
Ireland and the UK in efforts to follow the World 
Health Organisation’s advice to “Test, Test, Test”. 
Expansion of PCR testing is critical to gain control 
over the pandemic spread of COVID-19 and the 
world-wide shortage of lysis buffer is a rate limiting 
step.  Here we disseminate details of a lysis buffer 
formulation that came into existence as a 
consequence of a rapidly formed multi-centre 
collaboration.  A replacement lysis buffer for 
extraction of viral nucleic acids from respiratory 
samples was desperately needed by diagnostic 
laboratories.  A panel of new lysis buffer 
formulations was generated and validated for use 
in COVID-19 testing by virus-specific RT-PCR and 
are being distributed throughout Ireland. It is 
hoped that by sharing the formulation and 
validation, we can make it useful to others in the 
national and international scientific community. 
The key chemical constituent of the lysis buffer 
(guanidinium thiocyanate) has become scarce, 
scientists from the School of Microbiology, 
University College Cork, combined their long-held 
knowledge of lysis buffers for RNA extraction, with 
insights from published work relating to extraction 
of RNA using magnetic glass beads (Chomczynski & 
Sacchi, 1987; Hui He et al., 2017). Ultimately, they 
formulated a lysis buffer, which uses much less 
guanidinium thiocyanate than standard 
formulations appear to use (4 M compared to 6 M). 
Simultaneously, scientists at Teagasc, Fermoy were 
working on a different experimental formulation 
for lysis buffer (Boom et al., 1990). Four laboratory 
preparations in total were tested for efficacy by 
medical scientists based in the Clinical 
Microbiology Department at Cork University 
Hospital (CUH), who conducted validation 
experiments using positive and negative samples.  
After validation, pharma-based scientists, 
generously prepared a large volume of the much 
needed 4 M GITC lysis buffer for distribution by 
CUH. 
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Virology and RNA biology expertise: Dr Martina 
Scallan & Dr John Mac Sharry 
Buffer preparation: Dr John Mac Sharry & Dr 
Martina Scallan; Prof Paul Cotter & Paula O’Connor 
Evaluation of buffer preparations and validation 
for use for in-vitro diagnosis of patients tested for 
Covid-19: Senior medical scientists Catherine 
Dempsey & Isabelle O’Callaghan 
Risk Assessment for buffer preparation: Dr Edel 
Durack & Dr Sarah Hudson 
Co-ordination of scaling of preparation for 
distribution by CUH: Dr Humphrey Moynihan & Dr 
Conor Horgan 
Co-ordination/preparation of paper: Dr Brigid 
Lucey 
It should be noted that the following chemical 
preparation, after validation was selected for use 
with named commercial platforms and testing 
kits. We recommend that each centre adopting it 
in their laboratories should first validate it for use 
with their own systems. It is also advisable to 
provide a lot number with each batch prepared 
for traceability. 
The 4 M GITC lysis buffer was developed based on 
the published method of Chomczynski & Sacchi 
(1987), adapted for magnetic glass bead extraction 
(Hui He et al., 2017), and validated against 
recognised standards using positive and negative 
controls.  Details of the composition of 4 M GITC 
lysis buffer and for the preparation of 1 litre are 
given below. 
The lysis procedure used in the diagnostic 
laboratory mixes lysis buffer and sample 1:1, this 
generates a working concentration of 2 M GITC 
during the lysis step as reported to be optimal by 
Hui He et al., 2017. 
Buffer Composition: 
4 M guanidinium thiocyanate (GITC) 
55 mM* Tris-HCl 
25 mM EDTA (Ethylenediaminetetraacetic acid) 
3 % (v/v) Triton X-100 
0.01 % (w/v) Bromophenol blue 
(*NOTE: calculated from the total amount of 0.1 M 
Tris pH 7.6 added, diluted by the degree of volume 
expansion observed when the GITC goes into 
solution). 
Preparation of one litre of 4M Guanidinium 
thiocyanate (GITC)/ Triton X-100 Lysis buffer 
(please also read risk assessment): 
1. 472.75 g of GITC is brought into solution 
initially by adding 400 ml of 0.1 M Tris HCl pH 
7.6. This will require heating in a 65°C water 
bath and some shaking of the vessel (but with 
lid well secured). In our hands, once fully 
dissolved the volume of the solution was 600 
ml. 
2. Make up to 750 ml with 0.1 M Tris HCl pH 7.6. 
3. Add 50 ml of 0.5 M EDTA, mix. 
4. Add 30 ml Triton-X-100, mix 
5. Volume made up to 1 L with 0.04 % (w/v) 
bromophenol blue (DEPC-treated water can be 
used instead) 
Notes: 
• See Appendix 1 for chemical agent risk 
assessment sheet 
• Use laboratory coat, safety goggles, gloves, 
chemical respirator dust mask (N95 mask) 
• Open containers of guanidinium thiocyanate 
powder should be handled in a fume cabinet 
• The balance for weighing should be positioned 
outside the fume cabinet (but close by).  
Receiving vessel must have a lid that can be 
sealed for weighing 
• Significant chemical or physical hazards notable 
when preparing buffer: poisoning and 
environmental hazards 
• Buffers made up with DEPC-treated molecular 
biology grade water 
• A significant increase in volume is observed 
upon GITC dissolution and the degree of volume 
expansion was found to vary between 
preparations performed at different sites.  This 
may reflect variations related to the 
manufacture of GITC and/or storage conditions 
of the chemical and accentuates the need for 
individual site validation before use 
diagnostically.  
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Validation of the preparation was conducted using 
two different automated extraction instruments 
and two different detection instruments. 
The validation consisted of a comparison of the 
efficacy of extraction with four laboratory-
prepared buffers and both a Qiagen (RLT lysis 
buffer from an RNeasy kit Cat. No./ID: 79216) and 
a Roche external lysis buffer when testing positive 
(amplifying two Covid-19 specific targets) and 
negative controls. (In each case the extraction 
volumes were 200 l of buffer:200 l transport 
medium.) Both positive and negative controls 
incorporated an internal control. Detection of 
targets was compared for crossing point values 
during real time Polymerase Chain Reactions (RT 
PCR). 
Results 
Detection of targets was compared for crossing 
point values (Cp) for the four prepared buffers and 
the Roche external lysis buffer as shown in Table 1. 
Automated extraction was conducted using the 
Roche MagNa pure LC and the PCR was performed 
on the Roche z480 RT PCR instrument. On a second 
day, the 4 M GITC buffer was tested in comparison 
with Roche and Qiagen buffers, using the 
IndiMag48 extraction system and RT PCR was 
conducted on a Roche LightCycler II 480 (Table 2). 
On the basis of these combined data, the buffer 
containing 4 M GITC was confirmed as suitable for 
use with the diagnostic systems in CUH. Figure 1 
shows the relative performance of all buffers 
tested, measured using Cp values
 
Table 1. Comparison of the efficacy of four formulations of lysis buffer intended for the extraction of viral 
RNA from respiratory samples for Covid-19 testing when compared with the Roche external lysis buffer 
  
^Cp = Crossing point during the test reaction cycles at which test is denoted positive; The complete 
formulations for the 5.4 M, 6 M GITC preparations with Triton X-100 and the 4.75 M GITC formulation without 
Triton are not currently listed. pH values refer to the pH of 0.1 M Tris-HCl used in buffer preparation. 
 
Table 2. Comparison of the efficacy of 4 M GITC (with 3% Triton X-100) with Qiagen and Roche lysis buffers 
Sample type SARS CoV2 Cp^ B beta CoV Cp^ Internal Control Cp^ Lysis buffer 
Positive sample 22.40 22.36 27.48 Roche 
Negative sample Not Detected Not Detected 29.55 Roche 
Positive sample 21.98 22.50 27.61 Qiagen 
Negative sample Not Detected Not Detected 31.53 Qiagen 
Positive sample 22.79 21.78 28.32 4 M GITC 3% Triton 
Negative sample Not Detected Not Detected 31.56 UCC 
 
^Cp = Crossing point during the test reaction cycles at which test is denoted positive 
 





Positive sample 22.37 22.96 29.46 4 M GITC (pH7.6) with Triton 
Negative sample Not Detected Not Detected 31.42 4 M GITC (pH7.6) with Triton 
Positive sample 22.36 23.36 29.62 5.4 M GITC (pH6.4) with Triton 
Negative sample Not Detected Not Detected 31.18 5.4 M GITC (pH6.4) with Triton 
Positive sample 22.29 23.25 29.44 6 M GITC (pH7.6) with Triton 
Negative sample Not Detected Not Detected 32.98 6 M GITC (pH7.6) with Triton 
Positive sample 22.57 21.69 28.82 4.75 M GITC (pH 7.6) without Triton 
Negative sample Not Detected Not Detected 30.76 4.75 M GITC (pH 7.6) without Triton 
Positive sample 20.85 21.62 27.32 Roche Lysis buffer 
Negative sample Not Detected Not Detected 28.59 Roche Lysis buffer 
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Figure 1. Comparison of the performance of commercial and non-commercial buffers as indicated by Cp 
values (y-axis) when tested against positive and negative sample controls during real-time RT-PCR 
diagnostic test for Covid-19. 
 
Based on these data, the 4 M GITC lysis buffer was 
selected for future preparation and use when 
extracting respiratory samples for Covid-19. 
 
Discussion 
A 4 M GITC lysis buffer with 3 % (v/v) Triton X-100 
has been shown to work very well in COVID-19 RT-
PCR, it includes a detergent which helps to 
disintegrate the virus during extraction, 
bromophenol blue as a visual aid for addition of 
lysis buffer to clinical samples and has the 
advantage of using less of a scarce ingredient. The 
knowledge that 4 M guanidinium thiocyanate 
(GITC) is sufficient in this lysis buffer means the 
straitened global supply of this chemical can be 
shared more effectively to make more lysis buffer 
to perform more tests around the world and help 
the world to take back control against this 
pandemic virus.  
 
Heeding Dr Michael J. Ryan’s advice “Perfection is 
the enemy of the good when it comes to 
emergency management”, we do not want to delay 
in communicating our findings to the wider world. 
Further variations of the 4 M GITC lysis buffer 
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formulation can be tested, in particular 
formulations with graded increases in % w/v of 
Triton X-100. Work is ongoing to test if variations 
in the molarity of Tris-HCl affect lysis buffer 
performance. Of highest priority is to get the 
message out that this 4 M GITC lysis buffer works 
well.  In addition we observed that Qiagen’s RLT 
lysis buffer from RNeasy kits worked very well with 
the systems and processes in place in the 
diagnostic laboratory at Cork University Hospital. 
When Covid-19 testing began, the individual 
diagnostic microbiology hospital laboratories in 
Ireland agreed not to stockpile any of their 
resources from any of the other Irish hospital 
laboratories.  Through their professional body, the 
Academy of Clinical Science and Laboratory 
Medicine, they had daily meetings (using 
WhatsApp) to problem solve as a group where 
necessary. 
Normally, hospital laboratories buy in reagents 
that allow them to concentrate on the business of 
diagnosis of patients and the preparation of their 
own reagents is rare. However, a matter of 
particular concern was the unexpected short 
supply of one reagent (lysis buffer) needed to lyse 
the virus causing COVID-19, to facilitate RNA 
extractions and subsequent detection. In 
straitened times, society needs to pool its 
resources and expertise to best impact and this 
case study and validation represents a generous 
and rapid response from the scientific community, 
when called upon by the Academy of Clinical and 
Laboratory Medicine, at a time when large 
international commercial companies were unable 
to supply this vital reagent.  
In the midst of this combined effort, research and 
medical scientists in other parts of Ireland are 
communicating their validation results in turn.  
Part of the group effort in the case being described 
here is that of the two scientists in the University 
of Limerick, who prepared the risk assessment 
documentation for the report, while 
simultaneously making up buffer and supplying 
their nearest hospital laboratory at University 
Hospital Limerick.  
In an urgent situation, Irish scientists, academics 
and biopharma have worked collectively to pool 
expertise, technical know-how, chemicals from 
their research laboratories, their facilities, time, co-
ordination and communication skills along with 
determination to develop a suitable replacement 
lysis buffer at scale in less than two weeks. Like 
hospital laboratories, third level research 
laboratories rely on buying ready-to-go kits and 
reagents to speed up their research.  Fortunately, 
retention of the knowedge regarding the chemical 
composition of the buffers among the scientists 
allowed them to make up their own reagents from 
raw materials. 
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Appendix 1. Risk Assessment of agents used in the preparation of lysis buffer containing Guanidine 
Thiocyanate, Trizma Base, EDTA disodium salt, Triton-X and Bromophenol Blue. 
 
